Monitoring the response of bone metastases to treatment with MRI and PET

The most recent developments in magnetic resonance imaging (MRI) and positron emission tomography (PET) and how these techniques can be used to detect bone metastases at an early stage and to monitor the response of these to treatment is discussed in a new review and position statement, published in the European Journal of Cancer (2014; doi.org/10.1016/j.ejca.2014.07.002).

Imaging technologies are very useful in evaluating a patient's response to cancer treatment, and this can be done quite effectively for most tumors using Response Evaluation Criteria in Solid Tumors (RECIST). However, RECIST works well for tumors located in soft tissue, but not so well for cancers that spread to the bone, such as prostate and breast cancers. More effort, therefore, is needed to improve our understanding of how to monitor the response of bone metastases to treatment using MRI and PET. This new report addresses these needs.

The paper, published by investigators with the Imaging Group of the European Organisation for Research and Treatment of Cancer (EORTC), highlights the most recent developments in MRI and PET and elucidates how these techniques can be used to detect bone metastases at an early stage as well as monitor the response of these to treatment. They describe the current state of the art in PET and MRI, the strengths, weaknesses, and complementarity of various imaging techniques with respect to specific indications, and recommendations for choosing the most appropriate imaging technique.

“Assessing the response of metastases to treatment is something we do on a day to day basis, both in our oncology practice as well as for clinical trials. If the metastases occur in soft tissues, then we already have validated criteria, such as RECIST, that enable us to evaluate the response. A host of problems, however, limits our ability to measure the response to treatment of metastases found in bone. These range from the characteristics of bone metastatic disease, the structure of bone itself, to the sensitivity, specificity, and resolution of imaging methods available until now. We hope to resolve these issues, and our review is a step in the right direction,” said lead author Prof. Frederic Lecouvet of the Cliniques Universitaires Saint Luc in Brussels, Belgium.

Techniques such as MRI and PET have the potential to detect the spreading of a cancer into the bone marrow at an earlier stage and also determine the extent of this spread. This study will contribute toward making these techniques a routine part of oncology practice.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs